Media coverage about aTyr Pharma (NASDAQ:LIFE) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. aTyr Pharma earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.0638734467895 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have impacted Accern’s rankings:

LIFE has been the topic of several recent research reports. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research note on Wednesday, July 12th. ValuEngine raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of aTyr Pharma in a research note on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company. The company has an average rating of “Hold” and a consensus price target of $3.65.

Shares of aTyr Pharma (LIFE) traded down 3.70% during midday trading on Friday, reaching $2.60. 28,441 shares of the company’s stock traded hands. The company’s market capitalization is $61.98 million. aTyr Pharma has a 52 week low of $2.10 and a 52 week high of $4.45. The stock’s 50 day moving average is $3.26 and its 200-day moving average is $3.37.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.06. On average, analysts forecast that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect aTyr Pharma (LIFE) Share Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.